Stockreport

Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? [Yahoo! Finance]

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF Ironwood Pharmaceuticals ' IRWD sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adu [Read more]